Show simple item record

dc.contributor.authorMartín-Escolano, Rubén
dc.contributor.authorCebrián, Rubén
dc.contributor.authorMartín Escolano, Javier
dc.contributor.authorRosales Lombardo, María José 
dc.contributor.authorMaqueda Abreu, Mercedes 
dc.contributor.authorSánchez Moreno, Manuel 
dc.contributor.authorMarín Sánchez, Clotilde
dc.identifier.citationMartín-Escolano, R., Cebrián, R., Martín-Escolano, J., Rosales, M. J., Maqueda, M., Sánchez-Moreno, M., & Marín, C. (2019). Insights into Chagas treatment based on the potential of bacteriocin AS-48. International Journal for Parasitology: Drugs and Drug Resistance, 10, 1-8.es_ES
dc.description.abstractChagas disease caused by the protozoan parasite Trypanosoma cruzi represents a significant public health problem in Latin America, affecting around 8 million cases worldwide. Nowadays is urgent the identification of new antichagasic agents as the only therapeutic options available, Nifurtimox and Benznidazole, are in use for>40 years, and present high toxicity, limited efficacy and frequent treatment failures in the chronic phase of the disease. Recently, it has been described the antiparasitic effect of AS-48, a bacteriocin produced by Enterococcus faecalis, against Trypanosoma brucei and Leishmania spp. In this work, we have demonstrated the in vitro potential of the AS-48 bacteriocin against T. cruzi. Interesting, AS-48 was more effective against the three morphological forms of different T. cruzi strains, and displayed lower cytotoxicity than the reference drug Benznidazole. In addition, AS-48 combines the criteria established as a potential antichagasic agent, resulting in a promising therapeutic alternative. According to the action mechanism, AS-48 trypanocidal activity could be explained in a mitochondrion-dependent manner through a reactive oxygen species production and mitochondrial depolarization, causing a fast and severe bioenergetic collapse.es_ES
dc.description.sponsorshipThis work was supported by the Spanish Ministry of Economy and Competitiveness [grant numbers SAF2013-48971-C2-1-R, CSD2010- 00065], both including funds from the European Regional Development Fundings (ERDF), and the Ministry of Education of Spain [RM-E, grant number FPU14/01537].es_ES
dc.publisherElsevier Inc.es_ES
dc.rightsAtribución-NoComercial-SinDerivadas 3.0 España*
dc.subjectAntichagasic agentes_ES
dc.subjectDrug discoveryes_ES
dc.subjectTrypanosoma cruzies_ES
dc.titleInsights into Chagas treatment based on the potential of bacteriocin AS-48es_ES

Files in this item


This item appears in the following Collection(s)

Show simple item record

Atribución-NoComercial-SinDerivadas 3.0 España
Except where otherwise noted, this item's license is described as Atribución-NoComercial-SinDerivadas 3.0 España